These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30783204)

  • 1. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
    Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
    Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Hattori M; Ishiguro H; Masuda N; Yoshimura A; Ohtani S; Yasojima H; Morita S; Ohno S; Iwata H
    Breast Cancer; 2018 Jan; 25(1):108-117. PubMed ID: 28861862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
    Smith JW; Vukelja S; Hoffman AD; Jones VE; McIntyre K; Berrak E; Song JX; O'Shaughnessy J
    Clin Breast Cancer; 2016 Feb; 16(1):31-7. PubMed ID: 26433876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
    Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
    Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin mesylate in patients with refractory cancers: a Phase I study.
    Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
    Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
    Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
    Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
    Roviello G; Milani M; Gobbi A; Cappelletti MR; Zanotti L; Senti C; Bottini A; Strina C; Sigala S; Generali D
    Clin Breast Cancer; 2016 Jun; 16(3):e57-9. PubMed ID: 26943987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
    Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
    Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
    Koczywas M; Frankel PH; Synold TW; Lenz HJ; Mortimer JE; El-Khoueiry AB; Gandara DR; Cristea MC; Chung VM; Lim D; Reckamp KL; Lau DH; Doyle LA; Ruel C; Carroll MI; Newman EM
    Br J Cancer; 2014 Dec; 111(12):2268-74. PubMed ID: 25349975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
    Goel S; Swami U; Kumar K; Dittrich C; Reyderman L; Jain M; Aisner J; Song J; Petrylak DP
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):567-578. PubMed ID: 31190276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
    Sakiyama T; Tsurutani J; Iwasa T; Kawakami H; Nonagase Y; Yoshida T; Tanaka K; Fujisaka Y; Kurata T; Komoike Y; Nishio K; Nakagawa K
    Br J Cancer; 2015 Mar; 112(5):819-24. PubMed ID: 25654665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
    Smith J; Irwin A; Jensen L; Tedesco K; Misir S; Zhu W; Almonte A; He Y; Xie R; Olivo M; O'Shaughnessy J
    Clin Breast Cancer; 2020 Apr; 20(2):160-167. PubMed ID: 31980406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
    Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
    Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
    Chen L; Yan X; Luo T; Tian T; He P; Zhong X
    Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
    Marmé F; Gomez-Roca C; Graudenz K; Huang F; Lettieri J; Peña C; Trnkova ZJ; Eucker J
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):727-737. PubMed ID: 29468456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.